These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 668735)

  • 1. Active specific immunotherapy of advanced renal-cell carcinoma.
    Tykkä H; Oravisto KJ; Lehtonen T; Sarna S; Tallberg T
    Eur Urol; 1978; 4(4):250-8. PubMed ID: 668735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma patients. A thirteen-year follow-up study.
    Tallberg T; Tykkä H; Mahlberg K; Halttunen P; Lehtonen T; Kalima T; Sarna S
    Eur Urol; 1985; 11(4):233-43. PubMed ID: 2412827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disappearance of lung metastases during immunotherapy in five patients suffering from renal carcinoma.
    Tykkä H; Hjelt L; Oravisto KJ; Turunen M; Tallberg T
    Scand J Respir Dis Suppl; 1974; 89():123-34. PubMed ID: 4528514
    [No Abstract]   [Full Text] [Related]  

  • 4. Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study.
    Tykkä H
    Scand J Urol Nephrol Suppl; 1981; 63():1-107. PubMed ID: 6184775
    [No Abstract]   [Full Text] [Related]  

  • 5. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced renal cell carcinoma.
    deKernion JB; Lindner A
    Prog Clin Biol Res; 1982; 100():641-59. PubMed ID: 6183675
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of bone metastases from renal cell carcinoma achieved by combined therapy.
    Ferreira AM; Mendes JR
    Eur Urol; 1976; 2(2):100-1. PubMed ID: 971672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
    Blute ML; Amling CL; Bryant SC; Zincke H
    Mayo Clin Proc; 2000 Oct; 75(10):1020-6. PubMed ID: 11040850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant immunotherapy in non-metastatic renal adenocarcinoma].
    Sánchez de la Muela P; Zudaire Bergera JJ; Robles García JE; Isa Kroon W; de Castro Barbosa F; Aguera Fernández L; Rosell Costa D; Berián Polo JM
    Actas Urol Esp; 1990; 14(6):396-400. PubMed ID: 2080725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of disseminated renal cell carcinoma with transfer factor.
    Montie JE; Bukowski RM; Deodhar SH; Hewlett JS; Stewart BH; Straffon RA
    J Urol; 1977 May; 117(5):553-6. PubMed ID: 859196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy for renal cell carcinoma.
    McDonald MW
    J Urol; 1982 Feb; 127(2):211-7. PubMed ID: 6174737
    [No Abstract]   [Full Text] [Related]  

  • 16. [Palliative treatment of metastasized hypernephroma].
    Klippel KF; Altwein JE
    Dtsch Med Wochenschr; 1979 Jan; 104(1):28-31. PubMed ID: 83228
    [No Abstract]   [Full Text] [Related]  

  • 17. Advanced renal cell carcinoma: treatment with xenogeneic immune ribonucleic acid and appropriate surgical resection.
    Skinner DG; Dekernion JB; Brower PA; Ramming KP; Pilch YH
    J Urol; 1976 Mar; 115(3):246-50. PubMed ID: 943577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
    Taguchi S; Buti S; Fukuhara H; Otsuka M; Bersanelli M; Morikawa T; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
    PLoS One; 2017; 12(2):e0172341. PubMed ID: 28241027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.